Kawa A, Arakawa S
Jpn J Exp Med. 1987 Feb;57(1):79-81.
The case of a 67-year-old male with IgA multiple myeloma successfully treated with AS strain of vaccinia virus is reported. The intravenous injection of this virus strain caused a definite decrease in the levels of monoclonal IgA from 1,309 mg/dl in the early stage of the treatment to 432 mg/dl on the 96th day of the regime. NK cell activity rose from 20.0% on the 10th day to 33% on the 106th day of the treatment. No adverse effects were observed throughout the entire course of the treatment. These results strongly suggest that AS strain vaccinia virus is a most promising and safe agent for the treatment of human malignancy. The possible mechanism of the beneficial effects of this virus strain is also briefly discussed.
报告了一例67岁男性IgA多发性骨髓瘤患者成功接受痘苗病毒AS株治疗的病例。静脉注射该病毒株使单克隆IgA水平从治疗初期的1309mg/dl明显下降至治疗方案第96天的432mg/dl。NK细胞活性从治疗第10天的20.0%升至第106天的33%。在整个治疗过程中未观察到不良反应。这些结果有力地表明，痘苗病毒AS株是治疗人类恶性肿瘤最有前景且安全的药物。还简要讨论了该病毒株产生有益效果的可能机制。
